Nivolumab

A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma

We present a retrospective study of Ipi/Nivo in refractory MCC.

Real-world assessment of response to anti-PD1 therapy in advanced cutaneous squamous cell carcinoma

In the JAAD, we provide a real-world assessment of response to anti-PD1 therapy in advanced cutaneous squamous cell carcinoma.